Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer

Next Previous
X
Search
Trial Profile

A Phase 1/2 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SRA 737 (Primary) ; Cisplatin; Gemcitabine
  • Indications Anal cancer; Bladder cancer; Cervical cancer; Colorectal cancer; Ovarian cancer; Pancreatic cancer; Rectal cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Sierra Oncology

    • Most Recent Events

    • 15 Nov 2022 Results of safety profile, recommended phase 2 dose (RP2D), pharmacokinetics profile, and clinical activity of SRA737,published in the Clinical Cancer Research
    • 23 Sep 2020 Status changed from active, no longer recruiting to completed.
    • 22 May 2020 This trial has been completed in Austria according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top